In vivo Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies
A. Kopp, S. Dong, H. Kwon, T. Wang, A. A. Desai, J. J. Linderman, P. M. Tessier, G. M. Thurber
This study develops HALA antibodies that adjust ADC delivery based on tumor HER2 expression, improving efficacy across varying expression levels in preclinical models.
bioRxiv · Apr 6, 2024 · PreprintBioengineering